

Suven Discovery Scientific Presentations in 2011

241st ACS National Meeting March 27 – 31, 2011, Anaheim, CA, USA

1. Fused thiazolo tetrahydropyridinyl amides as potent and selective histamine H3 receptor antagonists
A Shinde et al.,
2. Novel aryl sulfonamides as potent, selective and brain penetrant 5-HT₆ receptor antagonists
Nirogi et al.,

International Conference on Alzheimer's disease (ICAD) July 17 - 21, 2011, Paris, France

3. Effect of various cognitive enhancers in acquisition task of radial maze.
R. Abraham et al.,
4. SUVN-502: A potent and selective 5-HT₆ antagonist, potential drug for the treatment of Alzheimer's disease.
Nirogi et al.,
5. Neurochemical Profile of SUVN-G1031, A Novel Histamine H3 Receptor Antagonist
N.Muddana et al.,
6. Neuronal nicotinic acetylcholine a4b2 receptor occupancy assay in rats using unlabelled ZW-104 as tracer
G.Bhyrapuneni et al.,
7. 5-HT₄ Receptor Agonist, SUVN-1004028, For the Treatment of Alzheimer's Disease.
I. Ahmad et al.,
8. SUVN-G1031, a novel selective H3 receptor antagonist in animal models of cognitive deficits.
P. Jayarajan et al.,

8th Annual Meeting & Exposition of the Controlled Release Society (CRS) July 30 – August 3, 2011, Maryland, USA

9. Effect of surface area by volume ratio on drug release in simulated gastric fluid and simulated intestinal fluid.
R. Manthri et al.,
10. Influence of dissolution media on the release of drug from HPMC matrix tablets.
K. Kurapati et al.,

242nd ACS National Meeting
August 28 - September 1, 2011, Denver, Colorado, USA

11. Novel amides as potent and selective histamine H3 receptor antagonists
Nirogi et al.,

International Society for the Study of Xenobiotics (ISSX)
October 16 - 20, 2011, Atlanta, USA

12. Effect of Pharmaceutical Vehicles on the Brain Penetration
N.Muddana et al.,
13. Evaluation of Mechanism Based CYP 450 3A Drug Interaction in Rats
V. Kandikere et al.,
14. Effect of Aripiprazole in an Animal Model of Alcohol Addiction and its Pharmacokinetics and Dopamine D2 Receptor Occupancy in Rats
G.Bhyrapuneni et al.,

Anxiety and Depression: 21st Neuropharmacology Conference
November 10 - 11, 2011, Virginia, USA

15. SUVN-911: A potent and selective nicotinic acetylcholine $\alpha 4\beta 2$ receptor antagonist for the treatment of mood disorders
Nirogi et al.,

Society of Neuroscience (SFN)
November 13 - 16, 2011, Washington, DC, USA

16. Evaluation of Adenosine A2A antagonist receptor occupancy using selective and potent unlabelled SCH442416 in the rat brain
R. S Saralaya et al.,
17. The impact of paw deformity on the assessment of mechanical allodynia in preclinical surgical pain models
P. Jayarajan et al.,
18. Neurochemical Effects of Histamine H3 Receptor Antagonists in the Brain of 6-Hydroxydopamine Lesioned Rats.
V.S. Benade et al.,
19. Selective H3 receptor ligands and their effect on rat brain regional tele-methyl histamine levels.
N.Muddana et al.,
20. Novel histamine H3 receptor antagonist SUVN-G1034 – Pharmacological profile.
V. Kandikere et al.,

21. SUVN-911 (nAChR $\alpha 4\beta 2$ antagonist) shows antidepressant like activity and addresses the limitation of current antidepressant therapy.
Nirogi et al.,
22. 5-HT₄ Receptor Agonist, SUVN-1004028, For the Treatment of Alzheimer's
I. Ahmad et al.,
23. Chronic high fat diet consumption: implications on cognitive function
D. Shanumganathan et al.,
24. Role of serotonin in the novel object recognition task.
R. Abraham et al.,